The present invention is relates to a compound of formula (I), X1, X2 and X3 are, independently of each other, N or CH； with the proviso that at least two of X1, X2 and X3 are N； Y is N or CH； R1 and R2 are independently of each other (i) a morpholinyl of formula (II) wherein the arrow denotes the bond in formula (I)； and wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(O)O-C1-C2alkyl； or R3 and R4 form together a bivalent residue -R5R6- selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2-, -CH2-NH-CH2-, or any of the structures wherein the arrows denote the bonds in formula (II)； or (ii) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7； wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl； or two R7 substituents form together a bivalent residue -R8R9- selected from C1-C3alkylene optionally substituted with 1 to 4 F, -CH2-O-CH2- or -O-CH2CH2-O-； with the proviso that at least one of R1 and R2 is a morpholinyl of formula II； and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof, for use in the prevention or treatment of a neurological disorder in a subject.本發明是關於一種式(I)化合物， 其中X1、X2及X3彼此獨立地為N或CH；其限制條件為，X1、X2及X3中的至少兩個是N；Y是N或CH；R1及R2彼此獨立地為(i)式(II)的嗎啉基 其中箭頭表示式(I)中的鍵；且 其中R3及R4彼此獨立地為H、視情況經一個或兩個OH取代的C1-C3烷基、C1-C2氟烷基、C1-C2烷氧基、C1-C2烷氧基C1-C3烷基、CN或C(O)O-C1-C2烷基；或R3與R4一起形成選自以下的二價殘基-R5R6-：視情況經1至4個F取代的C1-C3伸烷基、-CH2-O-CH2-、-CH2-NH-CH2-或以下結構中的任一者 其中箭頭表示式(II)中的鍵；或(ii)視情況經1至3個R7取代之選自硫代嗎啉基及哌嗪基的飽和6員雜環Z；其中R7在每次出現時獨立地為視情況經一個或兩個OH取代的C1-C3烷基、C1-C2氟烷基、C1-C2烷氧基C1-C3烷基、C3-C6環烷基；或兩個R7取代基一起形成選自視情況經1至4個F取代之C1-C3伸烷基、-CH2-O-CH2-或-O-CH2CH2-O-的二價殘基-R8R9-；其限制條件為，R1及R2中的至少一個是式II的嗎啉基；及其前藥、代謝物、互變異構物、溶劑合物及醫藥學上可接受的鹽，以
